Xarelto® (rivaroxaban) is a newer prescription anticoagulant, or blood thinner, marketed by Bayer and Johnson & Johnson. Xarelto® received FDA approval in 2011 to reduce the risk of strokes, blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip or knee replacement surgery.
Xarelto® is one of several drugs in a new class of anticoagulants (blood thinners) called direct factor Xa inhibitors. The first of these new class of drugs to gain FDA approval was Pradaxa®. The manufacturer of Pradaxa®, Boehringer Ingelheim, recently settled the lawsuits it was facing, agreeing to pay $650 million to approximately 4,000 people across the United States for similar bleeding injuries.
Xarelto® is like other blood thinners, in that it carries the risk of internal bleeding side effects. However, the internal bleeding caused by Xarelto®cannot be controlled or reversed by physicians, unlike the traditional class of blood thinners which include Coumadin® (warfarin). The Institute for Safe Medication Practices (ISMP) advises that Xarelto® has been associated with “serious, disabling or fatal injury,” including blood clots or thrombolytic events.
After filing one of the first Xarelto®cases in the country, senior partner Neil Overholtz was appointed by the federal judge overseeing all cases nationwide to the Plaintiff's Steering Committee. Mr. Overholtz was one of only 12 lawyers selected out of nearly 100 applicants nationwide. Mr. Overholtz has also been chosen to lead the discovery effort on behalf of Plaintiffs, as co-chair of the Plaintiff's Discovery Committee. That committee will focus its efforts on document investigation and depositions of corporate witnesses here in the US and in Europe where the drug was developed and tested.
If you or a loved one suffered a harmful side effect such as a stroke, blood clot, or internal bleeding while taking Xarelto®, you may have a valuable legal claim. Contact us today to speak with one of the attorneys on the forefront of Xarelto® litigation.